Your privacy is very important for us. When you visit our website, please agree to use all cookies. For more information about how we use cookies, please visit our Privacy Policy.

中

News Center

6756758(2)-91.jpg

LaNova Medicines Completes USD 42 Million Series C1 Financing to Accelerate Clinical Progress and Innovation Platform Development

Learn More

All

2025

2024

2023

2022

2021

2020

LaNova Medicines Announces the IND Approval of LM-305, a GPRC5D-targeting ADC Drug by NMPA

Shanghai November 10th, 2022 – LaNova Medicines Ltd. announces that the investigational new drug (IND) of LM-305, an ADC drug targeting GPRC5D, has been approved by China NMPA.

2022-11-10

Learn More
LaNova Medicines' LM-101 IND Submission is Accepted by China NMPA

2022-09-05

Learn More
LaNova Medicines' LM-305 Receives IND Acceptance by China NMPA

2022-09-03

Learn More
LaNova Medicines Announces IND Approval of LM-305 by US FDA

2022-07-30

Learn More
LaNova Medicines Announces the IND Approval of CCR8-targeting monoclonal antibody LM-108 by China NMPA

2022-06-01

Learn More
LaNova Medicines and Turning Point Therapeutics Enter Into a Licensing Agreement for LM-302

2022-05-05

Learn More

5